Lake Street analyst Thomas Flaten maintained a Buy rating on Journey Medical Corp (DERM – Research Report) today and set a price target of $9.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Thomas Flaten has given his Buy rating due to a combination of factors that indicate a strong growth potential for Journey Medical Corp. The company’s strategic launch of Emrosi, a premium product priced significantly higher than competitors, underscores its clinical advantages and market differentiation. This premium pricing strategy is expected to play a crucial role in capturing a substantial share of the dermatology market.
Moreover, despite a recent dip in share value, Journey Medical’s stock is currently undervalued compared to its peers, offering an attractive entry point for investors. The company’s well-established sales force and targeted approach towards key dermatology prescribers are poised to drive successful commercialization. These elements, coupled with anticipated revenue growth and improved gross margins, form the basis for maintaining the Buy rating and a price target of $9.
In another report released today, Roth MKM also maintained a Buy rating on the stock with a $11.00 price target.